Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy

SUMMARY While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo’s effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

show abstract

Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy

Cited by 19 publications

References 61 publications

Neurologic complications of chemotherapy and other newer and experimental approaches

Neurologic complications of chemotherapy and other newer and experimental approaches

Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies

Erythropoietin Stimulates Tumor Growth via EphB4

Contact Info

Product

Resources

About